secwatch.observer — SEC 8-K summary
======================================

Issuer:     Zura Bio Ltd (ZURA)
CIK:        0001855644
Form:       8-K
Filed at:   2024-11-07T23:59:59+00:00
Accession:  0001104659-24-115033
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Zura Bio Q3 net loss $22.9M; cash $188.2M; Phase 2 trials on track for SSc and HS
--------------------------------------------------------------------------------

- Net loss of $22.9M ($0.26 per share) vs $8.3M ($0.18) in Q3 2023; G&A up $7.1M on one-time stock comp and warrant exchange.
- Cash, cash equivalents and investments $188.2M as of Sep 30, 2024, up from $99.8M at Dec 31, 2023; expected to fund operations through 2027.
- Phase 2 trial of tibulizumab for systemic sclerosis expected to initiate Q4 2024; Orphan Drug Designation request submitted to FDA.
- Phase 2 trial of tibulizumab for hidradenitis suppurativa anticipated to start Q2 2025; IND submission expected Q1 2025.
- Completed warrant exchange in August 2024 and established ATM program for financial flexibility.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924115033/0001104659-24-115033-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1855644/000110465924115033/tm2427543d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-115033

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer